Emergent BioSolutions (NYSE: EBS) will further develop a licensed drug against Ebola under a potential 10-year, $704 million contract from
Eli Lilly and Co. (NYSE: LLY) has received a potential $375M contract from the departments of Defense and Health and…
Ology Bioservices has secured a pair of contracts worth $135.4M combined from the Department of Defense to develop a medical
